Hematopoietic Progenitor Cells
Loading...Hematopoietic Progenitor Cells Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
HPC (hematopoietic progenitor cells), Cord Blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
The risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells.
History
There is currently no drug history available for this drug.
Other Information
HPC, Cord Blood consists of hematopoietic progenitor cells, monocytes, lymphocytes, and granulocytes from human cord blood. Blood recovered from umbilical cord and placenta is volume reduced and partially depleted of red blood cells and plasma.
The active ingredient is hematopoietic progenitor cells which express the cell surface marker CD34. The potency of cord blood is determined by measuring the numbers of total nucleated cells (TNC) and CD34+ cells, and cell viability. Each unit of HPC, Cord Blood contains a minimum of 5 x 108 total nucleated cells with at least 1.25 x 106 viable CD34+ cells at the time of cryopreservation. The cellular composition of HPC, Cord Blood depends on the composition of cells in the blood recovered from the umbilical cord and placenta of the donor. The actual nucleated cell count, the CD34+ cell count, the ABO group, and the HLA typing are listed on the container label and/or accompanying records sent with each individual unit.
HPC, Cord Blood has the following inactive ingredients: dimethyl sulfoxide (DMSO) and Dextran 40. When prepared for infusion according to instructions, the infusate contains the following inactive ingredients: Dextran 40, human serum albumin, and residual DMSO.
Sources
Hematopoietic Progenitor Cells Manufacturers
-
Clinimmune Labs, University Of Colorado Blood Bank
![Hematopoietic Progenitor Cells, Cord Blood (Human Cord Blood Hematopoietic Progenitor Cell) Liquid [Clinimmune Labs, University Of Colorado Blood Bank]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Hematopoietic Progenitor Cells | Clinimmune Labs, University Of Colorado Blood Bank
For intravenous use only.
Do not irradiate.
2.1 DosingThe recommended minimum dose is 2.5 x 107 nucleated cells/kg at cryopreservation. Multiple units may be required in order to achieve the appropriate dose.
Matching for at least 4 of 6 HLA-A antigens, HLA-B antigens, and HLA-DRB1 alleles is recommended. The HLA typing and nucleated cell content for each individual unit of HPC, Cord Blood are documented on the container label and/or in accompanying records.
2.2 Preparation for InfusionHPC, Cord Blood should be prepared by a trained healthcare professional.
Do not irradiate HPC, Cord Blood. See the appended detailed instructions for preparation of HPC, Cord Blood for infusion. Once prepared for infusion, HPC, Cord Blood may be stored at 1 to 8°C for up to 4 hours. The recommended limit on DMSO administration is 1 gram per kg body weight per day. [See Warnings and Precautions (5.2)] 2.3 AdministrationHPC, Cord Blood should be administered under the supervision of a qualified healthcare professional experienced in hematopoietic progenitor cell transplantation.
Confirm the identity of the patient for the specified unit of HPC, Cord Blood prior to administration. Confirm that emergency medications are available for use in the immediate area. Ensure the patient is hydrated adequately. Premedicate the patient 30 to 60 minutes before the administration of HPC, Cord Blood. Premedications can include any or all of the following: antipyretic, histamine blocker, and corticosteroids. Inspect the product for any abnormalities such as unusual particulates and for breaches of container integrity prior to administration. Prior to infusion, discuss all such product irregularities with the laboratory issuing the product for infusion. Administer HPC, Cord Blood by intravenous infusion. Do not administer in the same tubing concurrently with products other than 0.9% Sodium Chloride, Injection (USP). HPC, Cord Blood may be filtered through a 170 to 260 micron filter designed to remove clots. Do NOT use a filter designed to remove leukocytes. For adults, begin infusion of HPC, Cord Blood at 100 milliliters per hour and increase the rate as tolerated. For children, begin infusion of HPC, Cord Blood at 1 milliliter per kg per hour and increase as tolerated. The infusion rate should be reduced if the fluid load is not tolerated. The infusion should be discontinued in the event of an allergic reaction or if the patient develops a moderate to severe infusion reaction. [See Warnings and Precautions (5) and Adverse Reactions (6)] Monitor the patient for adverse reactions during, and for at least six hours after, administration. Because HPC, Cord Blood contains lysed red cells that may cause renal failure, careful monitoring of urine output is also recommended.
Login To Your Free Account